52 results about "Cyclovirobuxine D" patented technology

A composition for treating skin pigmentation, a method of forming the composition, and a method of treating skin pigmentation are disclosed. The composition comprises at least one pharmaceutically acceptable additive. The composition further comprises at least one melanin production inhibitor, which may be a depigmentation agent. The melanin production inhibitor is present in an amount effective to inhibit melanin production in human skin cells of a subject that is administered the composition. The melanin production inhibitor is selected from the group consisting of cyclovirobuxine D, lipoic acid, nuciferine, peimisine, oleuropein, Rhodiola algida extract, Rhodiola kirilowii (Regel) Maxim extract, Glycyrrhizae Radix et Rhizoma extract, Cirsii japonici herba extract, Platycladi semen extract, Synotis erythropappa extract, Astragali complanati semen extract, Plantaginis semen extract, Lycopi herba extract, Euryales semen extract, Cuscutae semen extract, Amomi fructus extract, Tara seed extract, Platycladi cacumen extract, Eucommiae cortex extract, Dioscoreae rhizoma extract, Cirsii herba extract, and combinations thereof.

The invention discloses buxine. It is made up of cyclovirobuxine D, cyclovirobuxine D, and cyclovirobune C. And their weight content respectively is 60%-95%, 1.0%-30%, and 0.5%-20%. It also discloses buxine hydrochloride and its preparation method and their preparation. The formed product has clear composition and structure, effective quality control to ensure stable curative effect and easy to form various modern preparations. Its preparation technology is simple. And its cost is low.

A controlled release medicine containing the Chinese-medicinal component cyclovirobuxine D is composed of the core tablet consisting of cyclovirobuxine D, penetrating active substance, acidic substance and high-molecular compound, and the coating film prepared from high-molecular compound. Its advantage is constant release speed.

The invention relates to a hydrophilic polymer-boxwood alkaline extractive or a combination of a derivative thereof which is shown in a general formula (1), wherein, P is the hydrophilic polymer, which is selected from polyethylene glycol, polyglutamic acid, polyaspartic acid, polypropylene glycol, polyvinyl alcohol, polypropylene morpholine and a copolymer thereof; n is an integer, which does not exceed the total quantity of hydroxyl group and amino group on the D; L is a linking group, which is selected from groups formed by ester group, carbonate group, amide group, amide ester group, ether group, urethane group and acetal; D is the boxwood alkaline extractive or the derivative thereof, which is selected from groups formed by cyclovirobuxine D, cycloprotobuxine A, cycloprotobuxine C, cyclovirobuxine C and derivatives thereof. The combination improves the water solubility of boxwoods, and prolongs the cycle half-life thereof in the organism.

The invention discloses a Cyclovirobuxine-D raw material drug and high efficiency liquid chromatography mensuration for Cyclovirobuxine-D content in different kinds of preparation, and high efficiency liquid chromatography for impurity testing in Cyclovirobuxine-D. The fixed phase in chromatographic condition uses octadecyl silane linkage silica gel or octyl silane linkage silica gel as filling material; The mobile phase adopt formate (ammonium formate) damping fluid-methanol system, acetic acid (ammonium acetate) damping fluid-methanol system, formate (ammonium formate) damping fluid-acetonitrile system or acetic acid (ammonium acetate) damping fluid-acetonitrile system; Evaporation light scattering detector (ELSD) detects drift tube temperature; drift tube temperature: 20-150 degree centigrade;and gas flow rate: 0.1L / min- 6.0L / min, split-flow or not split stream sampling. The method is easy to operate, timesaving, and has strong expert attribute. It could effectively divide some kind of alkaloids that has with Cyclovirobuxine-D in Cyclovirobuxine-D raw material drug. Thus, it is able to accurately measure their content. The method could also detecting impurity in Cyclovirobuxine-D. The invention could also measure content degree of homogeneity of Cyclovirobuxine-D in boxwood-nin piece, boxwood-nin drop pill, and boxwood-nin powder pin. And it commendably satisfies the request of pharmacopoeia content and content degree of homogeneity testing.

The invention discloses a cyclovirobuxine D derivative and a preparation method and the application thereof. The structure of the derivative is shown as formula (I): R in the formula is selected from H, C1-6alkyl, phenyl, p-nitrophenyl, para halogen phenyl, para-C1-6alkyl substituted phenyl, para-C1-6alkoxy, para-trifluoromethyl-phenyl, para-dimethylamino-benzene base, inter-nitrophenyl, 3, 4-dimethyl-phenyl, 3, 4, 5- trimethyl-phenyl, 3, 4-dimethoxy-phenyl, 3, 4, 5-trimethoxybenzaldehyde base, 3-thiazolyl, 2-furyl or 1-naphthyl. The derivative can be prepared by taking cyclovirobuxine D and aldehydes (II) as raw materials. The derivative has the same effect as the cyclovirobuxine D, can be combined with pharmaceutically-acceptable auxiliary components into injection agent which can be used for treating cardiovascular and cerebrovascular disease and various oral pharmaceutical preparations.

The invention provides a cyclovirobuxine D sublingual tablet which is a preparation prepared from the following raw materials and auxiliary materials in parts by weight: 0.1-0.2 part of cyclovirobuxine D, 4-7 parts of lactose or pregelatinized starch, 3-5 parts of microcrystalline cellulose and 0.3-0.7 part of low-substituted hydroxypropyl cellulose. The invention further provides a preparation method and an application of the sublingual tablet. The sublingual tablet provided by the invention has small categories of auxiliary materials, high drug concentration, high disintegrating speed and excellent permeable membrane absorption, and can be effectively used for sublingual administration; in addition, after the raw materials and the auxiliary materials are mixed, a special dispersion technology is not needed for processing so that a forming process is simple and convenient, the production cost is low, and the industrial production is beneficial.

The invention provides a preparation method for cyclovirobuxinum D hydrochloride. The preparation method comprises the following steps: subjecting a crude product of cyclovirobuxinum D to recrystallization by using one or more selected from a group consisting of methanol, ethanol and chloroform; and dissolving a recrystallization product in an organic solvent, adding 1M dilute hydrochloric acid drop by drop, carrying out a reaction at room temperature for salt formation, then subjecting a precipitated salt to filtering and drying, then subjecting the dried salt and a mixed solvent of methanol and ethanol to heating reflux, and carrying out slow and natural cooling for crystallization after a solution is clear so as to obtain cyclovirobuxinum D hydrochloride. The preparation method provided by the invention is low in cost, simple to operate, easy to realize large-scale production, and high in yield, wherein the yield of the salt formation reaction is 90% or above; and the prepared cyclovirobuxinum D hydrochloride has HPLC purity of more than 99%.

The invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine raw material as well as a preparation and a use thereof, wherein the pharmaceutical raw material comprises cyclovirobuxine D and cycloprotobuxamine C. Studies find that the content of the cycloprotobuxamine C in the cyclovirobuxine D raw material is within a certain range, and the kidney toxicity of the raw material is significantly reduced; and pharmacodynamic tests prove that the cyclovirobuxine D pharmaceutical raw material disclosed by the invention has great effects of treating angina, coronary heart disease, arrhythmia and the like.

The invention relates to an electrochemical sensor, device and method for detecting cyclovirobuxine D. The electrochemical sensor comprises a glassy carbon electrode, a single-walled carbon nanotube is modified on the surface of the glassy carbon electrode, and polybromothymol blue is modified on the single-walled carbon nanotube. According to the invention, polybromothymol blue is used as a recognition element and an electrochemical probe of cyclovirobuxine D at the same time to construct the electrochemical sensor of cyclovirobuxine D, and quantitative analysis can be carried out on cyclovirobuxine D through the current change of the electrochemical sensor before and after the action with cyclovirobuxine D. The electrochemical sensor and the device are simple in preparation process, lowin cost, convenient to operate, high in analysis speed, sensitive in response, easy to update and reusable, and quantitative analysis of cyclovirobuxine D in various physiological samples can be realized. The electrochemical sensor, device and method provided by the invention have a wide application prospect in quality standard research of the cyclovirobuxine D and physiological and pathological events related to the cyclovirobuxine D.

The invention discloses a Cyclovirobuxine-D raw material drug and high efficiency liquid chromatography mensuration for Cyclovirobuxine-D content in different kinds of preparation, and high efficiency liquid chromatography for impurity testing in Cyclovirobuxine-D. The fixed phase in chromatographic condition uses octadecyl silane linkage silica gel or octyl silane linkage silica gel as filling material; The mobile phase adopt formate (ammonium formate) damping fluid-methanol system, acetic acid (ammonium acetate) damping fluid-methanol system, formate (ammonium formate) damping fluid-acetonitrile system or acetic acid (ammonium acetate) damping fluid-acetonitrile system; Evaporation light scattering detector (ELSD) detects drift tube temperature; drift tube temperature: 20-150 degree centigrade;and gas flow rate: 0.1L / min- 6.0L / min, split-flow or not split stream sampling. The method is easy to operate, timesaving, and has strong expert attribute. It could effectively divide some kind of alkaloids that has with Cyclovirobuxine-D in Cyclovirobuxine-D raw material drug. Thus, it is able to accurately measure their content. The method could also detecting impurity in Cyclovirobuxine-D. The invention could also measure content degree of homogeneity of Cyclovirobuxine-D in boxwood-nin piece, boxwood-nin drop pill, and boxwood-nin powder pin. And it commendably satisfies the request of pharmacopoeia content and content degree of homogeneity testing.

The invention discloses Huangyangning dispersible tablets and a preparation method thereof. Raw materials are subjected to nanocrystallization with a supercritical fluid method, then Cyclovirobuxine D, soybean lecithin, PEG4000, microcrystalline cellulose, hydroxypropyl cellulose, aerosil and aspartame are granulated with an equivalent incremental method by use of 60% ethyl alcohol, and drying and tableting are performed. Compared with Huangyangning on the market, the dispersible tablets have characteristics of high solubility and dissolution rate, quick absorption, high bioavailability and the like; the quality of the dispersible tablets can be better improved and development of drugs is facilitated.

The invention belongs to the technical field of traditional Chinese medicines and discloses a traditional Chinese medicine raw material as well as a preparation and a use thereof, wherein the pharmaceutical raw material comprises cyclovirobuxine D and cycloprotobuxamine C. Studies find that the content of the cycloprotobuxamine C in the cyclovirobuxine D raw material is within a certain range, and the kidney toxicity of the raw material is significantly reduced; and pharmacodynamic tests prove that the cyclovirobuxine D pharmaceutical raw material disclosed by the invention has great effects of treating angina, coronary heart disease, arrhythmia and the like.